Sage Therapeutics to seek approval of postpartum depression drug after trial win

The Cambridge biotech said this morning it plans to apply for FDA approval of its experimental drug to treat postpartum depression next year after the drug achieved the main goals in two late-stage trials involving more than 200 women.